Acute bronchitis primary prevention

Revision as of 18:25, 17 April 2012 by Vanbot (talk | contribs) (Robot: Changing Category:Mature chapter to Category:Overview complete)
Jump to navigation Jump to search

Chronic Obstructive Pulmonary Disease Page

Bronchitis Main Page

Acute bronchitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Acute bronchitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Acute bronchitis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute bronchitis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute bronchitis primary prevention

CDC on Acute bronchitis primary prevention

Acute bronchitis primary prevention in the news

Blogs on Acute bronchitis primary prevention

Directions to Hospitals Treating Acute bronchitis

Risk calculators and risk factors for Acute bronchitis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Onset can be mitigated through various prevention methodologies. Vaccinations serve to as an effective mechanism for primary prevention.

Prevention

In 1985, University of Newcastle, Australia Professor Robert Clancy developed an oral vaccine for acute bronchitis. This vaccine was commercialized four years later as Broncostat.[1]

References

  1. Broncostat. Biotechnology.com. Retrieved on October 3 2007.


Template:WikiDoc Sources